Skip to main content

Lumigan Timolol FDA Approval Status

FDA Approved: No
Brand name: Lumigan Timolol
Generic name: bimatoprost and timolol
Dosage form: Ophthalmic Solution
Company: Allergan, Inc.
Treatment for: Glaucoma

Lumigan Timolol (bimatoprost and timolol) is a prostamide analog and beta-adrenergic antagonist combination intended for the treatment of open-angle glaucoma or ocular hypertension. In August 2004, Allergan, Inc. announced the receipt of an Approvable Letter from the U.S. Food and Drug Administration (FDA) advising the conditions the company must meet in order to obtain final FDA marketing approval. While Lumigan Timolol is approved as Ganfort in the UK, it remains commercially undeveloped in the United States.

Development timeline for Lumigan Timolol

Aug  2, 2004Allergan Receives Approvable Letter for Lumigan Timolol Combination

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.